Population pharmacokinetic modelling to optimise treatment for children with Rifampicin-resistant TB and HIV
Thesis / Dissertation
2024
Permanent link to this Item
Authors
Journal Title
Link to Journal
Journal ISSN
Volume Title
Publisher
Publisher
University of Cape Town
Department
Faculty
License
Series
Abstract
The global burden of rifampicin- and/or multidrug-resistant (RR/MDR) -TB, i.e. Mycobacterium tuberculosis resistant to rifampicin and/or isoniazid is increasing, especially in settings with high HIV prevalence. Optimising the prevention and treatment of RR/MDR-TB in children in such settings is critically important. Population pharmacokinetic modelling, the state-of-the art technique to interpret pharmacological data, can play a pivotal role for therapeutic optimization in children, since it enables characterisation and inclusion of the effects of important developmental factors, thus allowing for determination and evaluation of effective yet safe RR/MDR treatment in children.
Description
Reference:
Van der Laan, L.E. 2024. Population pharmacokinetic modelling to optimise treatment for children with Rifampicin-resistant TB and HIV. . University of Cape Town ,Faculty of Health Sciences ,Department of Medicine. http://hdl.handle.net/11427/41299